The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Prognostic value of metastatic sites in patients with mCRC treated with regorafenib
Cristina Smolenski, MD, Gustave Roussy, Villejuif, France, discusses the prognostic value of different metastatic sites in the Phase II PRODIGE 68 – UCGI 38 – SOREGATT trial (NCT04450836) of regorafenib and trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer (mCRC). Results indicated no significant differences in overall survival (OS) and progression-free survival (PFS) across metastatic site groups, though ECOG status was associated with better OS. Further studies are required for better patient selection. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
